CD7 CAR-T

BIOLOGICAL2 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd., Guangzhou Bio-gene Technology Co., Ltd

Conditions

T-Cell Acute Lymphocytic LeukemiaT-cell Acute Lymphoblastic Leukemia/Lymphoma

Phase 1

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

CompletedNCT04572308

Hebei Senlang Biotechnology Inc., Ltd.T-cell Acute Lymphoblastic Leukemia/Lymphoma

Start: 2020-10-01End: 2021-05-30Updated: 2021-06-29

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

WithdrawnNCT05909527

Guangzhou Bio-gene Technology Co., LtdT-Cell Acute Lymphocytic Leukemia

Start: 2023-05-01End: 2028-08-01Updated: 2026-03-17

Related Papers

CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study

Blood2025-11-03

CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma

Blood2025-11-03

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Blood2023-11-022 citations

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Blood2023-11-021 citations

Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with <scp>CD7</scp>‐targeted chimeric antigen receptor‐T cell therapy

American Journal of Hematology2023-09-2344 citations

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

HemaSphere2023-08-011 citations

Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial

Blood2022-05-02122 citations

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Blood2021-11-0511 citations

Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia

Blood2021-11-053 citations